Communications with, and Criticism by, FDA in Analyzing Obviousness, PTAB Litigation Blog

Visit the PTAB Litigation Blog.

On April 26, 2019, the Federal Circuit affirmed three final written decisions of the Patent and Trial Appeal Board ("Board") in related inter partes reviews ("IPRs") in which the Board upheld the patentability of all the claims of U.S. Patent 7,772,209 ("the ’209 patent") over obviousness challenges.

Read the full article at

Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.